12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AX200: Development discontinued

In its 4Q11 earnings, Sygnis said it would evaluate potential M&A options and financing opportunities after discontinuing development of AX200 to treat stroke. Sygnis said an analysis of data from the double-blind, European Phase II AXIS 2 trial of AX200 showed "no hints of efficacy." In December, Sygnis reported top-line...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >